Cwm LLC Has $7.39 Million Stock Holdings in GSK plc (NYSE:GSK)

Cwm LLC trimmed its stake in GSK plc (NYSE:GSK) by 2.7% in the fourth quarter, HoldingsChannel reports. The firm owned 199,322 shares of the pharmaceutical company’s stock after selling 5,594 shares during the period. Cwm LLC’s holdings in GSK were worth $7,387,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Versant Capital Management Inc grew its holdings in GSK by 2,816.7% in the fourth quarter. Versant Capital Management Inc now owns 700 shares of the pharmaceutical company’s stock worth $26,000 after purchasing an additional 676 shares during the period. Larson Financial Group LLC grew its holdings in GSK by 271.8% in the third quarter. Larson Financial Group LLC now owns 885 shares of the pharmaceutical company’s stock worth $32,000 after purchasing an additional 647 shares during the period. BKM Wealth Management LLC acquired a new stake in GSK in the fourth quarter worth $32,000. Jones Financial Companies Lllp grew its holdings in GSK by 62.2% in the third quarter. Jones Financial Companies Lllp now owns 1,327 shares of the pharmaceutical company’s stock worth $48,000 after purchasing an additional 509 shares during the period. Finally, Washington Trust Advisors Inc. acquired a new stake in GSK in the third quarter worth $53,000. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Stock Up 2.1 %

Shares of NYSE GSK opened at $40.60 on Tuesday. The stock has a market capitalization of $84.14 billion, a P/E ratio of 13.49, a P/E/G ratio of 1.40 and a beta of 0.64. The company has a 50-day moving average price of $41.88 and a 200-day moving average price of $38.86. GSK plc has a 1 year low of $33.33 and a 1 year high of $43.84. The company has a debt-to-equity ratio of 1.19, a current ratio of 0.88 and a quick ratio of 0.62.

GSK (NYSE:GSK) last released its quarterly earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.72 earnings per share for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.04). GSK had a net margin of 16.24% and a return on equity of 51.45%. The firm had revenue of $10 billion for the quarter, compared to the consensus estimate of $9.79 billion. On average, equities research analysts forecast that GSK plc will post 4.03 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, April 11th. Investors of record on Friday, February 23rd were given a dividend of $0.3564 per share. This is a positive change from GSK’s previous quarterly dividend of $0.34. This represents a $1.43 dividend on an annualized basis and a dividend yield of 3.51%. The ex-dividend date of this dividend was Thursday, February 22nd. GSK’s dividend payout ratio (DPR) is presently 52.82%.

Wall Street Analyst Weigh In

GSK has been the subject of a number of analyst reports. Citigroup upgraded shares of GSK from a “neutral” rating to a “buy” rating in a report on Tuesday, February 13th. Guggenheim upgraded shares of GSK from a “neutral” rating to a “buy” rating in a report on Monday, March 4th. Morgan Stanley initiated coverage on shares of GSK in a report on Tuesday, January 23rd. They set an “equal weight” rating for the company. Finally, Jefferies Financial Group upgraded shares of GSK from a “hold” rating to a “buy” rating in a report on Wednesday, January 3rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, GSK has an average rating of “Moderate Buy”.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.